Aarti Drugs Limited · NSE:AARTIDRUGS

Aarti Drugs — Investor Presentation (May 2015)

23 slides from Aarti Drugs's investor presentation, May 25, 2015

  1. Slide 1: Aarti Drugs Ltd Corporate Presentation

    Aarti Drugs Ltd Corporate Presentation May 25, 2015 (update)

  2. Slide 2: Disclaimer

    Disclaimer Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward looking statements that involve a number of risks and uncertainties. Although Aarti Drugs attempts to be accurate i

  3. Slide 3: About Aarti Drugs

    About Aarti Drugs OVERVIEW  Part of the $ 650 million Aarti Group of Industries, the company was established back in 1984  It is engaged in manufacturing of APIs, Pharma Intermediates and specialty chemicals with 10 multi-ton, multi-location GMP compliant facilities  8 facilities located in Indus

  4. Slide 4: About Aarti Drugs (Cont.) - Awards & Recognition

    About Aarti Drugs (Cont.)  Various products are registered with various authorities like USFDA, COS, IDL, JAPAN ACCREDITATION, TGA, COFEPRIS, ANVISA, WHO-GMP, EUGMP  It has developed 30 new molecules in the past five years AWARDS & RECOGNITION Year Authority Awards 2013 ABBOTT Best Vendor of the y

  5. Slide 5: About Aarti Drugs - Vision and Mission

    About Aarti Drugs Vision  To be the preferred vendor for products in India and World Mission  Seek global market leadership  Focus on growth and development of the product  Continue to create winning culture, operating in highest standards of ethics and values with co-operation among competitors

  6. Slide 6: Shareholding structure

    Shareholding structure Promoters Shareholding 70.00% 60.00% 50.00% 40.00% 30.00% 20.00% 10.00% 60.10% 55.57% 57.43% 59.61% 42.57% 40.39% 39.90% 0.00% FY 11-12 FY 12-13 FY 13-14 FY 14-15 m= Promoters Public & Others

  7. Slide 7: Timelines

    Timelines 2014 – Turnover of Rs. 1000 Crore 2010- Turnover of RS. 500 Crore 2008- Approval of USFDA Plant 1997- Turnover of Rs. 100 Crore 1996 – Amalgamation of RCIL, RCPL, MCPL, MPPL & EPCL 1993- Listed On Stock Exchange 1984 - Incorporation (BSE & NSE)

  8. Slide 8: Leadership Team

    Leadership Team Mr. Prakash M.  Founder Director of Aarti Drugs Ltd Patil  Excels in an array of promotional activities viz : product identification, project Chairman, MD conceptualization, planning, project engineering & project implementation & CEO  Bachelor of Chemical Engineering From UDCT Mr

  9. Slide 9: Business overview

    Business overview Segmentwise Sales For FY 14-15 API's MFormulation Speciality Chemicals mIntermediates & others Therapeuticwise Sales for FY 14-15 @ Antibiotic B Antiprotozoals. & Antiinflammatory @ Antifungal @ Antidiabetic § Cardioprotectant § Others Segmentwise Sales For FY 13-14 HAPIs Formulati

  10. Slide 10: Business overview - Product Specific Leadership

    Business overview Product Specific Leadership Largest producer in Ciprofloxacin / India and 2nd largest in Enrofloxacin the world Tinidazole Largest producer in the world Largest producer in Metronidazole India / JV in China Metronidazole Largest producer in Benzoate the world Largest producer in Ke

  11. Slide 11: Business overview

    Business overview • ADL is domestic market share leader in most of its top 10 products • Export Clientele is well diversified with the topmost client contributing to only 3.77% of total export sales • Top ten export clients contributes to only 24.80% of total export sales • Top ten products contribu

  12. Slide 12: Geographic presence

    Geographic presence TOP 10 EXPORT COUNTRIES : Regulated 60% Country Country Semi-Regulated 10% BRAZIL TURKEY Non - Regulated 30% BANGLADE MEXICO SH NETHERLAN SPAIN DS EGYPT CHINA IRAN PAKISTAN

  13. Slide 13: Key local clientele

    Key local clientele Sr. % To Total Local No. Customer Name Sales 1 J.B. Chemicals & 4.48% Pharmaceuticals Ltd 2 Cipla Limited 4.43% 3 Alkem Laboratories Ltd 3.66% 4 Abbott Healthcare Pvt Ltd 3.33% 5 Zydus Healthcare Ltd 2.43% 6 Hetero Labs Ltd 2.28% 7 Zoetis India Limited (Pfizer) 2.12% 8 Micro Labs

  14. Slide 14: Overview of facilities

    Overview of facilities As of August 2014 Sr. No. Name of Unit Certification Australian Government – Department of Health and Ageing - Therapeutic Goods Administration 1. Aarti Drugs Ltd.E-22 WHO-GMP / Japanese Accreditation USFDA- Depart of Health and Human Services ANVISA-Brazil 2 Aarti Drugs Ltd.G

  15. Slide 15: Overview of facilities - Reaction Capabilities

    Overview of facilities Reaction Capabilities  Nitration  Sulphonation  Cyclocondensation  Alkylation  Ammonolysis (Amidation )  Methoxylation  Epoxidation (Chiral & Achiral)  Halogenation (CI, Br, I)  Reduction  Acetylation  Dehalohydrogenation  Diazotization & Related  Condensation Che

  16. Slide 16: Focus on quality

    Focus on quality  Establish and maintain high standards of quality of its products manufactured at various locations including those at contract manufacturing sites, meeting cGMP & cGLP norms  Comply with current national and international regulations as applicable and continuously move towards me

  17. Slide 17: R&D focus

    R&D focus  Manufacturing facilities supported by R&D team which is located at Tarapur  Strength at R&D • Doctorates : 03 • Master Graduates [M. Sc] : 36 • Graduates [B. Sc] : 11 • Engineers : 25 • Technicians : 12  Pilot plant facility at corporate R&D center in Tarapur, which is suitable to manu

  18. Slide 18: Future business strategy

    Future business strategy  Anti Diabetic: • Received EC approval in April’15. Commercial operations will start by end of 1st Qtr • Expected revenues of installed capacity would be ~150 cr per annum as per ROW market pricing. Designed for highly regulated markets. Layout has been designed for doublin

  19. Slide 19: Future business strategy – contd

    Future business strategy – contd……  Vitamins / Anti-Inflammatory: • Multi-purpose facility under construction. Targeting highly regulated markets • Installed capacity will give revenues of around 50 Cr/ 35 Cr per annum as per product selection - Currently on HOLD  R&D product pipeline: • Strong pi

  20. Slide 20: Summary of financials - 1

    Summary of financials - 1 Al Turnover Profit Before Tax & proft After Tax 1400 120 1200 1169.94 100.06 1044.35 100 1000 885.75 2 80 800 699.18 60 600 400 40 200 20 ° 0 FY 11-12 FY 12-13 FY 13-14 FY 14-15 FY 44-42 FY12-13 Fy 13-14 Fy14-15 mRsin Crore mRsin Crore ™Rsin Crore Networth Earning Per Share

  21. Slide 21: Summary of financials - 2

    Summary of financials - 2 Book Value (Bonus Issue 1:1 on 26-Mar-15) Dividend Payout 140 30 - 125.41 26.95 26.77 25.51 94.96 103.61 25 100 873 20 19.37 80 72.88 - 15.74 60 15 12.11 40 10 . , a 0 0 FY 11-12 FY 12-13 FY 13-14 FY 14-15 FY 11-12 FY 12-13 FY 13-14 F¥ 14-15 = Amount in Rs mRsinCrore m% Ret

  22. Slide 22: Summary of financials - 3

    Summary of financials - 3 Financial Overview (Rs in crores) Audited Mar '12 Mar '13 Mar '14 Mar '15 Equity Share Capital 12.11 12.11 12.11 24.22 Reserves 164.37 195.50 238.80 279.48 Net worth 176.48 207.61 250.91 303.70 Secured Loans 209.72 240.22 284.96 331.92 Unsecured Loans 88.20 80.29 93.73 102.

  23. Slide 23: Thank You

    THANK YOU Please visit our website for additional information like Annual Reports & addresses of registered offices: Website: www.aartidrugs.com For any further information please contact us at: Aarti Drugs Ltd Mahendra Inds. Estate, Ground Floor, Plot No. 109-D Road No. 29, Sion (E), Mumbai-400 022

Aarti Drugs — Investor Presentation (May 2015) on 6ix